AUROBINDO PHARMA LIMITED announced that the US FDA inspected its wholly owned subsidiary, Eugia Pharma Specialities Limited’s Unit-III facility from January 27 to February 06, 2026. The inspection concluded with 11 observations. The FDA has now classified this inspection as ‘Official Action Indicated’ (OAI). The company stated there is no impact on its financials or operations due to this classification, reaffirming its commitment to high-quality manufacturing standards.
US FDA Inspection at Eugia Unit-III
AUROBINDO PHARMA LIMITED has disclosed that the United States Food and Drug Administration (US FDA) conducted an inspection at its wholly owned subsidiary’s facility, Eugia Pharma Specialities Limited, Unit-III. This facility is a formulation manufacturing unit located at Phase-III, TSIIC, EPIP, IDA, Pashamylaram, Patancheru Revenue Mandal, Sangareddy District, Telangana.
Inspection Details and Classification
The inspection took place from January 27 to February 06, 2026, and resulted in 11 observations. Following the inspection, the US FDA has determined the classification of this facility to be ‘Official Action Indicated’ (OAI).
Company’s Commitment and Impact
AUROBINDO PHARMA LIMITED emphasized its ongoing commitment to maintaining the highest quality manufacturing standards across all its global facilities. The company has also stated that there is no impact on its financial, operational, or other activities resulting from this inspection classification.
Disclosure Information
This disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Further details regarding the inspection are provided in the attached Annexure.
Source: BSE
